Variable clinic-EEG trajectories in male patients with PCDH19 clustering epilepsy

INTRODUCTION / ВВЕДЕНИЕ

The association between the protocadherin-19 (PCDH19) gene and epilepsy suggests that its X-linked inherited pathogenic variant is asymptomatic in males and affects solely females causing the syndrome of epilepsy and mental retardation (Epilepsy Limited to Females with Intellectual Disability, EFMR) also identified as Julberg–Hellman syndrome or PCDH19 clustering epilepsy [1][2]. However, recent data have described males with mosaic pathogenic variants of the PCDH19 gene [3], displaying clinical picture similar to the common manifestations of the disease in females.

The PCDH19 gene is located on the long arm of the X chromosome (Xq22.1) encoding the protein protocadherin-19 (protocadherin-19) [4], a transmembrane protein being involved in neuronal organization and mediating cell migration. It is expressed at high level during neurogenesis in the hippocampus and cortex but found at low amount in the white matter of the brain [3][5]. Protocadherin is required for calcium-dependent cell-cell communication and adhesion. Total or partial PCDH19 gene deletion or alternation within the coding region can result in loss of function of the PCDH19 gene, leading to emergence of cells with impaired intercellular interaction.

PCDH19 expression declines postnatally but remains detectable, with the brain being its predominant site in adulthood. In addition, recent studies have highlighted the role of PCDH19 in reducing the generation of certain neurosteroid hormones such as cortisol and allopregnalonone followed by potentiated seizure susceptibility [6][7].

Pathogenic variants of the PCDH19 gene are associated with early onset of cluster epileptic seizures, often triggered by fever, cognitive impairment of varying severity, as well as behavioral disorders such as autism, attention deficit and hyperactivity disorder, and aggression. Clinical features may mimic Dravet syndrome (OMIM: 300088, MIM phenotype № 300088) [3].

MATERIAL AND METHODS / МАТЕРИАЛ И МЕТОДЫ

We present a report on three new cases of PCDH19 clustering epilepsy in male patients with developmental delay, drug-resistant cluster seizures, febrile seizure provocation, and early onset. The data on presented male cases were collected at diverse centers through personal communication between authors inferring that the structured patient cohort was not assessed.

For all patients, an NGS-based¹ custom epilepsy gene panel and whole-exome sequencing were performed by using NextSeq 500 (Illumina Inc., USA). An in-house software pipeline was used, designed to detect single-nucleotide variants (SNVs). All gene variants and their de novo status were confirmed by Sanger sequencing in blood and buccal epithelium specimens.

Video electroencephalogram (VEEG) was performed in the state of active and passive wakefulness, sleep, as well as during functional tests for standard protocol approved by the International Federation of Clinical Neurophysiology (IFCN) and the International League Against Epilepsy (ILAE) multiple times by using non-shared equipment.

According to the HARNESS-MRI (harmonized neuro-imaging of epilepsy structural sequences magnetic resonance imaging) epilepsy protocol, brain MRI was performed multiple times for all patients by using non-shared equipment (1.5 and 3 Tesla).

Detailed clinical data were collected from patient medical records.

Ethical aspects / Этические аспекты

The case report study was conducted according to the guidelines of the Declaration of Helsinki of the World Medical Association (Fortaleza, Brazil, 2013). The patients’ parents received a comprehensive information and provided written informed consent.

RESULTS / РЕЗУЛЬТАТЫ

All patients displayed similar clinical picture: onset at age ranging from 5 to 8 months, with disease course including focal attacks in clusters, sensitivity to fever, speech development disorders, neurological and behavioral abnormalities combined with mild to moderate mental retardation. At the time of manuscript preparation, all patients were receiving valproic acid as part of a polytherapy, and one patient was undergoing vagus nerve stimulation. Two patients (at the age of 7 and 11 years old, respectively) were in remission lasting for more than 1 year, and one patient (at the age of 12 years old) suffered from frequent cluster seizures [6].

Whole-exome sequencing / Полноэкзомное секвенирование

Due to the bilateral febrile provoked nature of the cluster seizures, a monogenic etiology was suspected, and an NGS-based custom epilepsy gene panel and whole-exome sequencing were performed by using NextSeq 500 (Illumina, USA). An in-house software pipeline was applied designed to detect gene SNVs. All patients had the following mosaic pattern of PCDH19 gene (NM_001184880.1) variants: Patient T. – a previously described variant chrX:99663134G>C (p.Tyr154Ter) [ PMID: 32425876]; Patient S. – a previously described variant chrX:99661914G>C (p.Pro561Arg) [ PMID: 32425876]; Patient K. – a previously described variant chrX:99663003C>G (p.Arg198Pro) [ PMID: 23712037, PMID: 26765483, PMID: 19214208]. All variants and their de novo status were confirmed by Sanger sequencing in blood and buccal epithelium specimens (Fig. 1).

Electroencephalography / Электроэнцефалография

It should be underlined that both at the disease onset and during therapy the electroencephalographic (EEG) data revealed a diffuse slowdown of the background rhythm. All patients showed interictal regional/multiregional epileptiform activity and ictal focal pattern in the frontotemporal regions (Fig. 2).

Magnetic resonance imaging / Магнитно-резонансная томография

Brain MRI performed at age of 3 years old showed in two patients delayed myelination without focal abnormalities (Fig. 3).

Detailed patients' clinical information is presented in Table 1.

DISCUSSION / ОБСУЖДЕНИЕ

A pathogenic variant of the PCDH19 gene was first described in 2009 in a male with somatic mosaicism. This discovery inspired to propose a theory for the disease pathogenesis: PCDH19 clustering epilepsy occurs when two distinct cell populations coexist within the same host (cells expressing normal and aberrant PCDH19 protein counterparts) that putatively disrupts intercellular communication (Fig. 4). It may account for why heterozygous carriers (females) are susceptible to the disease onset, whereas homozygotes (men) become ill only in the case of somatic mosaicism [3].

PCDH19 promotes cell adhesion specificity in a combinatorial manner so that mosaic PCDH19 expression in heterozygous female mice results in targeted sorting between wild-type PCDH19-positive and -negative cells in developing cortex that correlates with altered neural activity. Complete deletion of the PCDH19 gene in heterozygous mice removes abnormal cell sorting and restores normal network activity [8].

Randomly inactivated X chromosome in females results in emergence of somatic mosaicism due to a mixture of both normal and abnormal protocadherin expressing-cell types. Such somatic mosaicism elicits alterations in interplay between both cell types followed by dysfunctional cell sorting and synaptogenesis. In contrast, males with hemizygous mutations generate only one cell type bearing certain protocadherin deficient subclass, but remain asymptomatic due to the lack of cellular intervention. However, for males with somatic mosaicism of the PCDH19 gene, a phenotype resembling that of heterozygous females is typical that results from altered cellular crosstalk between both distinct cell types [7][9–14].

Both girls and boys display similar clinical picture of epilepsy associated with the PCDH19 gene mutation (girls clustering epilepsy PCDH19-GCE) that includes early onset of the disease (at the age of 6–36 months, on average at the age of 4–18 months); generalized tonic-clonic or/and focal epileptic seizures, often provoked by fever; short seizures with a cluster course; and pharmacoresistance [1][2][15][16]. The disease is featured with a progressive course along with rising seizure rate and seizure number per a cluster, gradually developing mental retardation of varying severity [17–19]. Three clinical stages of PCDH19-GCE have been identified: clusters of seizures without fever within the first 2 years of life, clusters of seizures during fever between age of 2 and 10 years old, and rare epileptic seizures and behavioral disturbances observed at age over 10 years old. We registered and described clusters of epileptic seizures in patients under the age of 2 years old [20].

Patients with PCDH19-GCE may be also observed to show stereotypical movements, hyperreflexia, autism spectrum disorders, and other neuropsychiatric disorders with aggression, obsessive disorders, schizophrenia, hysteria, depression, a tendency to self-harm as well as attention deficit in case of hyperactivity disorder [14][18][21].

The rate of seizures in PCDH19-GCE girls often declines during puberty potentially due to hormonal changes [17][20][22–24]. However, an age-related decrease in seizure rate was reported in the patients examined as well as some other identified male patients. Therefore, this tendency seems unlikely to occur solely in females being associated with female hormones [6]. N. Higurashi et al. (2015) suggest that remission of seizures in adolescence occurs due to maturation of the blood-brain barrier [25].

The PCDH19 protein is expressed stronger in endothelial cells in the central nervous system than in other organs. N. Higurashi et al. (2015) consider that seizures, resulting from PCDH19 gene mutation usually occur in the limbic region located closer to the periventricular regions [25].

EEG often shows focal or multifocal epileptiform changes and background slowdown [26]. Registration of focal and multifocal activity based on EEG data alerts researchers to the presence of structural changes in patient brain. Four out of five girls with focal cortical dysplasia (FCD) were recorded to have multifocal changes, and one girl – diffuse changes without focal activity [27].

MRI data often reveal a variant of the normal pattern. In addition, various cortical malformations have been identified in patients with epilepsy associated with PCDH19-GCE [8]. Study by N. Trivisano et al. (2018) detected FCD in 4% patients, with 10% of them suspected to have same diagnosis [22].

Similar data were observed in a series of studies: in 3 patients reported by Y. Tan et al. (2018) [8]; in 2 patients – by A. Liu et al. (2019) [15]; and in 6 to 9 patients – by I.M. de Lange et al. (2017) [3]. A dilated perivascular and subarachnoid spaces were found in 2 out of 9 observed patients reported in the study by I.M. Lange et al. (2017) [3] similar to MRI changes in found by us in Patient K.

Analysis of MRI images reveals cortical sulcus abnormalities in 4 girls with PCDH19-GCE [23]. The patients had various cerebral cortex abnormalities, including dysplasia of the bottom of the sulcus, abnormal cortex fold, thickened cortex as well as blurred transition between gray and white matter [8][23]. M. Kurian et al. (2018) described an improved seizure control in 2 patients after FCD resection [27].

The coincidence between pathogenic PCDH19 variants and cortical malformations including FCD remains controversial. FCD may not occur accidentally and could be accounted for by a putative role that PCDH19 might play in neuronal migration demonstrated in some animals or in vitro in human pluripotent stem cell-derived neurons [5][11][27][28].

However, the process of abnormal cell sorting and its potential to cause the above alterations have not yet been well understood. The variability of the abnormalities is consistent with the random X-chromosome inactivation as well as the phenotypes observed in patients with PCDH19-GCE [8][29][30].

It is likely that males with about 50% brain mosaicism intrinsically bearing high level of cellular interference may display a more severe clinical picture than males with a lower or higher percentage of mosaicism [3]. The high or low percentage of mosaicism resembles that of skewed X-inactivation in female patients, which has also been thought to result in a milder phenotype [26][30], which, however, revealed no clear correlation [7][21][25][31].

The generation of differential adhesion affinity in neuronal progenitor cells induced by mosaic PCDH19 expression appears underlie the essential cellular mechanism responsible for the unique X-linked inheritance for PCDH19-GCE. Even the lack of PCDH19 observed in hemizygous males results in no emergence of incompatible adhesion specificity that allows for normal position of neuronal progenitor cells and neural activity. An abnormal rearrangement of neuronal progenitor cells in the nascent cortex of the heterozygous brain points that at least some of their neuronal descendants may be located aberrantly, regardless of whether they support postpartum PCDH19 expression. Such reorganization may disrupt functional boundaries of the cortex and affect links between cortical and subcortical regions [8].

If the entire cerebral cortex were to undergo segregation, it might likely lead to aberrant organization of the functional cortical columns. In case an abnormal cell sorting occurs throughout the cortex, a difference in neuronal architecture between humans and mice could contribute to a more severe phenotype observed in PCDH19-GCE patients [8].

In addition, the identification of altered cortical sulcus suggests that aberrant cell sorting may cause diverse morphological phenotypes in the gyrencephalic vs. lissencephalic brain. The cortical fold of the human brain largely results from varying proliferation of the basal radial glia cells comprising a small proportion of progenitor cells in the lissencephalic vs. gyrencephalic brain [8][29][32]. The overgrowth of the basal radial glia cells triggers formation of “wedges” emerging from cell dense areas that ultimately accounts for brain fold. Segregation within basal radial glial cells in developing human brain may result in abnormal development due to improper “wedge” formation [8].

On the other hand, neurodevelopmental disorders associated with mutations in other non-clustered members belonging to the protocadherin family (NC PCDH) may be caused by impaired cell adhesion affinity [8][33][34]. It is likely that mosaic disruption of adhesion specificity occurs via a process other than X-inactivation primarily due to random monoallelic NC PCDH expression [35]. Individuals with a heterozygous germline mutation in certain autosomal NC PCDHs may bear some cells expressing either a functional or a non-functional allele resulting in impaired adhesion specificity. The proportion of cells affected by random monoallelic NC PCDH expression is likely to affect the penetrance or expressivity of any resulting phenotype [8].

The in vivo interaction of the relevant adhesion affinities for each of such closely related families of NC PCDH proteins can lead to diverse outcomes. The coordinated expression of grouped protocadherins is believed to result in repulsion involved in neuron self-recognition [8][36][37]. On the other hand, it has been shown that NC PCDH-expressing cells are able to selectively interact in vivo. Given the multi-layered and overlapping pattern of NC PCDH expression throughout development, it seems likely that this property might regulate spatial arrangement of neuronal cell progenitors to be potentially exploited during the morphogenesis of other organs [8][38].

Thus, the loss of PCDH19 is associated, e.g., with altered columnar organization and elevated cell proliferation in the optical membrane [24][27] additionally triggering brain hyperexcitability in zebrafish models [39]. Although no major morphological defects were observed in the mutant brain, the loss of mouse PCDH19 similarly enhances neuronal cell migration [27][28].

Cerebral cortical malformations comprise an important cause of developmental abnormalities and PCDH19-GCE, so that some of them are related to defects in specific genes [22v40]. When FCD emerges, the co-occurrence of pathogenic variants of SCN1A is not considered to account for the overall clinical picture, but the loss or dysfunction of the relevant protein, action of susceptibility factors and genetic modifiers of phenotypic expression may collectively play a certain role [41]. In addition, MRI signs related to FCD were detected in patients with other monogenic forms of epileptic encephalopathies [42]. Such associations discussed here by us highlight a need for further study to provide deeper insights into underlying mechanisms and, consequently, examination and clinical management of such patients [43–45].

CONCLUSION / ЗАКЛЮЧЕНИЕ

Early recognition of the above features should improve early diagnostics and long-term management of patients with epilepsy coupled to PCDH19 mutations. In this context, MRI plays a unique role in establishing the phenotypic signature of such associations in vivo. It is important to note that a specialized assessment is required prior to drawing a conclusion that no structural changes in the brain take place. Stereotypical focal epileptic seizures observed in such patient cohort require exclusion of structural changes in the brain as well as performing pre-surgical examination.